1.	Phase III Randomized Study of Immunotherapy With Polyvalent Melanoma Vaccine (Canvaxin™) Plus BCG Versus BCG Plus Placebo After Surgery in Patients With Stage IV Melanoma Phase: Phase III Type: Treatment Status: Completed Age: 18 to 80 Sponsor: NCI Protocol IDs: JWCI-MC-4-001, CV-MMAIT-4-001, RPCI-DS-98-16, NCI-G98-1492, NCT00052156
2.	Phase III Randomized Study of BCG Plus a Polyvalent Melanoma Vaccine (Canvaxin™) Versus BCG Plus Placebo in Patients With Resected Stage III Melanoma Phase: Phase III Type: Treatment Status: Completed Age: 18 to 80 Sponsor: NCI Protocol IDs: JWCI-MC-3-001A, CV-MMAIT-3-001, NCI-V99-1576, NCT00052130
3.	Phase II Randomized Study of Polyvalent Melanoma Vaccine Encapsulated into pH-Sensitive Liposomes in Patients with Stage IIB or III Malignant Melanoma (Summary Last Modified 03/2000) Phase: Phase II Type: Treatment Status: Closed Age: 18 to 75 Sponsor: NCI Protocol IDs: NYU-9615, NCI-G98-1488
4.	Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma Phase: Phase II Type: Treatment Status: Completed Age: 18 to 75 Sponsor: NCI, Other Protocol IDs: CDR0000067323, NYU-9837, NCI-G99-1595, NCT00004104
5.	Phase II Study of Polyvalent Melanoma Vaccine (Canvaxin™) in Patients With In-Transit Cutaneous Malignant Melanoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Closed Age: 18 to 80 Sponsor: Pharmaceutical / Industry Protocol IDs: CV-MMAIT-5-001, NCT00128583